Cell-free DNA (cfDNA) derived from tumours is present in the plasma of cancer patients. The
majority of currently available studies on the use of this circulating tumour DNA (ctDNA) deal …

Techniques for analyzing circulating tumor DNA (ctDNA) to detect, characterize and monitor
cancer have matured rapidly. An increasing body of clinical evidence is demonstrating the …

Minimally invasive approaches to detect residual disease after surgery are needed to
identify patients with cancer who are at risk for metastatic relapse. Circulating tumour DNA …

Purpose: We assessed whether perioperative circulating tumor DNA (ctDNA) could be a
biomarker for early detection of molecular residual disease (MRD) and prediction of …

Circulating tumor DNA (ctDNA) has emerged as a biomarker with wide-ranging applications
in cancer management. While its role in guiding precision medicine in certain tumors via …

Importance Adjuvant chemotherapy in patients with stage III colon cancer prevents
recurrence by eradicating minimal residual disease. However, which patients remain at high …

Testing peripheral blood for circulating tumor DNA (ctDNA) offers a minimally invasive
opportunity to diagnose, characterize, and monitor the disease in individual cancer patients …

PURPOSE Earlier detection of cancer recurrence using circulating tumor DNA (ctDNA) to
detect molecular residual disease (MRD) has the potential to dramatically affect cancer …

The term liquid biopsy (LB) refers to the use of various biological fluids as a surrogate for
neoplastic tissue to achieve information for diagnostic, prognostic and predictive purposes …

In the era of personalized medicine and targeted therapies for the management of patients
with cancer, ultrasensitive detection methods for tumor genotyping, such as next-generation …